Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
HEALTH
Insmed Drug for Chronic Lung Ailment Meets Main Endpoint in Trial
By Scott Van Voorhis
Feb 3, 2020 1:26 PM EST
PRESS RELEASES
Insmed To Host Conference Call To Discuss Topline Data From Treprostinil Palmitil Inhalation Powder Phase 1 Study
By PR Newswire
Feb 16, 2021 8:00 AM EST
PRESS RELEASES
Insmed To Host Fourth Quarter And Full Year 2020 Financial Results Conference Call On Thursday, February 25, 2021
By PR Newswire
Feb 12, 2021 8:00 AM EST
PRESS RELEASES
Insmed To Present At The 39th Annual J.P. Morgan Healthcare Conference
By PR Newswire
Jan 5, 2021 8:00 AM EST
PRESS RELEASES
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
By PR Newswire
Dec 4, 2020 8:00 AM EST
PRESS RELEASES
Insmed Announces Initiation Of Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis
By PR Newswire
Dec 2, 2020 8:00 AM EST
PRESS RELEASES
Insmed To Present At The Evercore ISI 3rd Annual HealthCONx Conference
By PR Newswire
Nov 24, 2020 8:00 AM EST
PRESS RELEASES
Insmed Receives Priority Medicines (PRIME) Designation From European Medicines Agency (EMA) For Brensocatib In Patients With Non-Cystic Fibrosis Bronchiectasis (NCFBE)
By PR Newswire
Nov 13, 2020 8:00 AM EST
PRESS RELEASES
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
By PR Newswire
Nov 6, 2020 8:00 AM EST
PRESS RELEASES
Insmed To Present At Two November Conferences
By PR Newswire
Nov 2, 2020 8:00 AM EST
PRESS RELEASES
Insmed To Host Third Quarter 2020 Financial Results Conference Call On Thursday, October 29, 2020
By PR Newswire
Oct 20, 2020 8:00 AM EDT
PRESS RELEASES
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
By PR Newswire
Oct 2, 2020 8:00 AM EDT
PRESS RELEASES
Insmed Highlights Progress Across Portfolio And Outlines Growth Strategy At R&D Day
By PR Newswire
Sep 30, 2020 8:00 AM EDT
PRESS RELEASES
Insmed To Host R&D Day On September 30, 2020
By PR Newswire
Sep 16, 2020 8:00 AM EDT
PRESS RELEASES
Insmed To Present At Three September Conferences
By PR Newswire
Sep 9, 2020 4:05 PM EDT
PRESS RELEASES
New England Journal Of Medicine Publishes Positive Results From Phase 2 WILLOW Study Of Brensocatib In Patients With Non-Cystic Fibrosis Bronchiectasis
By PR Newswire
Sep 7, 2020 11:24 AM EDT
PRESS RELEASES
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
By PR Newswire
Sep 4, 2020 8:00 AM EDT
PRESS RELEASES
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
By PR Newswire
Aug 7, 2020 8:00 AM EDT
PRESS RELEASES
Insmed To Host Second Quarter 2020 Financial Results Conference Call On Thursday, August 6, 2020
By PR Newswire
Jul 27, 2020 8:00 AM EDT
PRESS RELEASES
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
By PR Newswire
Jul 6, 2020 8:00 AM EDT
PRESS RELEASES
Positive Results From Phase 2 WILLOW Study Of Brensocatib In Patients With Non-Cystic Fibrosis Bronchiectasis Presented At ATS Virtual Clinical Trials Session
By PR Newswire
Jun 24, 2020 4:01 PM EDT
PRESS RELEASES
Insmed Receives FDA Breakthrough Therapy Designation For Brensocatib In Patients With Non-Cystic Fibrosis Bronchiectasis (NCFBE)
By PR Newswire
Jun 8, 2020 8:00 AM EDT
PRESS RELEASES
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
By PR Newswire
Jun 5, 2020 8:00 AM EDT
PRESS RELEASES
Insmed To Present At Two June Conferences
By PR Newswire
May 26, 2020 8:00 AM EDT
PRESS RELEASES
Insmed To Showcase New Brensocatib Data At American Thoracic Society Virtual Clinical Trials Session
By PR Newswire
May 20, 2020 9:29 AM EDT
